| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,320 | 4,400 | 13:04 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| Fr | ASCENTAGE-B Has Six Studies Selected for Abstracts at American Society of Clinical Oncology Annual Meeting | 1 | AASTOCKS | ||
| Fr | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | 72 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company... ► Artikel lesen | |
| Fr | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST CLINICAL DATA FROM MULTIPLE TRIALS AT ASCO 2026 | 1 | HKEx | ||
| Do | ASCENTAGE-B (06855): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| Mi | ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026 | 1 | HKEx | ||
| Mo | TGI Solar Power Group, Inc.: TGI Solar Power Group CEO Samuel Epstein Elected Secretary/Editor of AAPG House of Delegates; Company Accelerates AXINOD Sovereign AI Strategy | 329 | ACCESS Newswire | Company Concurrently Signals Expansion into High-Growth Sovereign AI Market with AXINOD Modular Infrastructure Strategy MIAMI, FL / ACCESS Newswire / May 18, 2026 / TGI SOLAR POWER GROUP INC. (OTC Markets:TSPG)... ► Artikel lesen | |
| 14.05. | Ascentage Pharma: Interview With Co-Founder & CEO Dr. Dajun Yang About The Global Hematology-Oncology Company | 4 | pulse2.com | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 13.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress | 1 | GlobeNewswire (USA) | ||
| 12.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.04. | ASCENTAGE-B (06855): SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026 | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SUPPLEMENTAL CIRCULAR - PROPOSED GRANTS UNDER THE 2022 RSU SCHEME AND POST-IPO SHARE OPTION SCHEME TO DR. YANG AND DR. ZHAI; AND ... | - | HKEx | ||
| 29.04. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 29.04. | ASCENTAGE-B (06855): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026 | 2 | HKEx | ||
| 29.04. | ASCENTAGE-B (06855): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 29.04. | ASCENTAGE-B (06855): PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED ... | 3 | HKEx | ||
| 28.04. | ASCENTAGE-B (06855): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 28.04. | ASCENTAGE-B (06855): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 24.04. | Truist reiterates Ascentage Pharma stock rating on pipeline progress | 4 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,35 | +1,67 % | Übernahme Kandidaten für 2026! Heiß wird es im LifeScience-Sektor bei Evotec, BioNxt, BioNTech und Formycon! | Die Börse hat sich in den letzten Monaten primär auf HighTech und Rüstung konzentriert. Der gesamte BioTech-Sektor wurde damit links liegen gelassen. Kurzfristig mag diese Strategie für Investoren aufgegangen... ► Artikel lesen | |
| OCUGEN | 1,176 | +2,08 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,350 | -1,13 % | Could Viking Therapeutics Be the Next Eli Lilly? | ||
| INFLARX | 2,250 | -0,18 % | EILMELDUNG bei InflaRx NV: Was Insider zum Wochenstart bereits wissen - Was Sie vor Montag noch wissen müssen | ||
| EDITAS MEDICINE | 2,310 | -2,94 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,620 | +0,97 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,154 | +1,05 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 58,60 | +0,69 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting | Allschwil, Switzerland, April 15, 2026
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 65,10 | +0,84 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BofA Securities 2026 Healthcare Conference May 12-14, 2026
Type:... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,189 | +0,34 % | Telix Pharmaceuticals Limited: IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,663 | +0,45 % | Onco-Innovations stärkt Qualitätstests für den PNKP-Inhibitor-Arzneimittelkandidaten | Vancouver, Kanada - 15. Mai 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zugeben, dass es... ► Artikel lesen | |
| TWIST BIOSCIENCE | 52,68 | +0,96 % | Leerink raises Twist Bioscience stock price target on AI growth outlook | ||
| REPLIGEN | 93,00 | -6,21 % | Repligen Corporation: Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report | ||
| UNIQURE | 20,850 | 0,00 % | uniQure Inc.: uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates | ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
~ Progressing AMT-130 toward expected UK regulatory submission; MAA on... ► Artikel lesen | |
| PHARMAMAR | 100,60 | +0,20 % | PHARMA MAR, S.A.: The Company announces the call of the Ordinary General Shareholders' Meeting and submits proposed resolutions. |